Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qigui Fuyuan Tang is a Traditional Chinese Medicine (TCM) herbal decoction primarily indicated for the treatment of ischemic stroke and its associated neurological deficits, such as hemiplegia and sensory loss. The formula is constructed based on the TCM theory of "tonifying Qi and activating blood" (Yi Qi Huo Xue), typically containing *Astragalus membranaceus* (Huangqi) and *Cinnamomum cassia* (Guizhi) as its principal ingredients. Pharmacological studies indicate that the decoction exerts neuroprotective effects by promoting angiogenesis through the upregulation of VEGF, reducing neuroinflammation by inhibiting pro-inflammatory cytokines like TNF-alpha, and preventing neuronal apoptosis via the modulation of the Bcl-2/Bax ratio and inhibition of Caspase-3. It is frequently evaluated in clinical settings in China for its ability to improve the National Institutes of Health Stroke Scale (NIHSS) scores and activities of daily living in post-stroke patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qigui Fuyuan Tang.